To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

• Status: RECRUITING
• Trial end date: 2026-12-31

Summary

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer

• Phase: PHASE2

Details

• Lead Sponsor: RemeGen Co., Ltd.
• Treatments: Cyclophosphamide; disitamab vedotin; Epirubicin; Injections; toripalimab